EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

What published GLP-1 cash prices are useful comparison anchors?

Dose Diligence research deskSection 03 · Page 5 of 12Last updated 17 Nov 2026

Use public prices to test patient affordability, not to infer clinic acquisition cost or negotiate from an assumed wholesale margin. The offers below are selected, publicly verifiable access options—not an exhaustive lowest-price search or a treatment recommendation.

Different molecules, presentations and doses are not assumed to be clinically interchangeable. A prescriber must determine the appropriate product and treatment plan; procurement should model that plan rather than generate one.

Product and presentationPublished self-pay anchor retrievedConditions that matter to the cost model
Zepbound single-dose vials or single-patient-use KwikPen$299 for 2.5 mg; $399 for 5 mg; $449 for 7.5–15 mg under the applicable purchase offerThe higher-dose offer requires qualifying refill purchases within 45 days. Without it, published regular prices are $499 for 7.5 mg and $699 for 10–15 mg. A programme month is 28 days. (lilly.com)
Wegovy injection pensEligible new patients: $199 for each of the first two monthly fills at 0.25 mg and 0.5 mg, through December 31, 2026; standard listed offer $349 for 0.25–2.4 mgEligibility applies; the page defines a month as four pens. Wegovy HD 7.2 mg is separately listed at $399. Do not assume introductory pricing applies to existing patients or continues into 2027. (novocare.com)
Wegovy tablets$149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg and 25 mgThe current patient page defines a month as 30 tablets. Do not carry forward the expired $149 promotion for 4 mg from an older price guide. (novocare.com)
Foundayo tablets$149 at 0.8 mg and temporarily at 2.5 mg; temporarily $199 at 5.5 mg; $299 at 9 mg and, conditionally, 14.5 mg and 17.2 mgReduced 2.5 mg and 5.5 mg prices run through December 31, 2026. The highest two strengths have a 45-day refill condition for the stated offer. A month is 30 days. (lilly.com)

Additional charges and eligibility restrictions can apply. Lilly's Zepbound page specifies separate needle or syringe purchases for the relevant presentations. Obtain a patient-facing final checkout amount, not just the medicine headline. (lilly.com)

Important scope limit: Newly reported multi-month offers were not independently verified in accessible manufacturer terms during this review. They are excluded rather than assumed unavailable. Before issuing a patient price commitment, ask the dispensing channel to confirm every currently eligible offer in writing.

Should insurance and Medicare access be compared with cash pay?

Yes—before placing a patient into a self-pay default. CMS describes a Medicare GLP-1 Bridge demonstration running from July 1, 2026, through December 31, 2027, with a $50 copay for eligible beneficiaries and eligible drugs. It operates outside the Part D benefit payment flow; the copay does not count toward Part D true out-of-pocket spending. It is not universal GLP-1 coverage. (cms.gov)

Build separate workflow branches for confirmed coverage, unresolved benefits, eligible public-programme access and cash pay. Do not assume a manufacturer copay card, a self-pay offer and an insurance benefit can be combined; the relevant programmes have distinct terms. (lilly.com)

Does oral versus injectable access change procurement?

It changes the quotation and workflow fields, not the rule that clinical selection comes first. The current programmes include oral and injectable presentations with different pack definitions and price conditions. (novocare.com)

Require separate product records for each presentation. Test packaging, storage instructions, patient education, refill timing and support scripts individually; do not inherit an injection workflow unchanged for a tablet product.

Explore the table row by row

A working view of the research

Zepbound single-dose vials or single-patient-use KwikPen

Published self-pay anchor retrieved
$299 for 2.5 mg; $399 for 5 mg; $449 for 7.5–15 mg under the applicable purchase offer
Conditions that matter to the cost model
The higher-dose offer requires qualifying refill purchases within 45 days. Without it, published regular prices are $499 for 7.5 mg and $699 for 10–15 mg. A programme month is 28 days. (lilly.com)

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/zepbound/zepbound-tirzepatide-full-terms-conditions
  2. novocare.com · Source 2 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  3. lilly.com · Source 3 ↗https://www.lilly.com/lillydirect/foundayo
  4. lilly.com · Source 4 ↗https://www.lilly.com/lillydirect/zepbound
  5. cms.gov · Source 5 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
Section sources →